在癌症转移和药物耐药性中解码平衡:高选择性DNA酶基细胞内K+传感器的见解
Zhenglin Yang1, Xiangli Shao1, Yuting Wu1
1Department of Chemistry, University of Texas at Austin, Austin, Texas 78712, United States.
Journal of the American Chemical Society
|May 14, 2025
概括
研究人员开发了一种新的离子 (K+) 传感器来监测癌细胞的K+水平. 这种工具揭示了晚期癌症细胞内K+的下降,并显示了细胞外K+如何影响化疗耐药性,这表明了新的治疗策略.
科学领域:
- 生物化学
- 分子生物学
- 癌症研究
背景情况:
- 离子 (K+) 和K+通道失调对于癌细胞的生存和免疫规避至关重要.
- 精确监测细胞内K+平衡对于了解癌症进展至关重要.
- 现有的K+成像探测器缺乏选择性,适当的动态范围和广泛的可访问性.
研究的目的:
- 为细胞内离子 (K+) 检测开发一种高度选择性和可访问的光传感器.
- 研究K+在癌细胞进展和化学抵抗中的作用.
主要方法:
- 在体外选择一种针对K+的新型RNA分裂DNA酶.
- 开发具有高选择性 (>1000倍与Na+相比) 和适当的动态范围 (21200mM) 的K+特异性DNA酶光传感器.
- 用该传感器监测乳腺癌细胞中的细胞内K+并评估细胞外K+对化疗疗效能的影响.
主要成果:
- 开发的传感器对其他生物相关离子具有特殊的选择性.
- 在更晚期的乳腺癌中,细胞内K+水平逐渐下降.
- 细胞外K+升高会降低抗癌药物 (ML133,阿米奥达龙) 的疗效,而阻断Kir2.1通道会恢复敏感性.
结论:
- 在瘤进展和化疗抵抗中,K+平衡起着重要作用.
- 新的K+特异性DNA酶传感器是研究癌症离子动态的宝贵工具.
- 向离子通道是一个有前途的策略来克服侵袭性癌症的化学阻力.
相关概念视频
Treatment Resistant Cancers
3.2K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.2K
Adaptive Mechanisms in Cancer Cells
5.6K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.6K
Combination Therapies and Personalized Medicine
4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
Metastasis
5.5K
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
5.5K


